LIMASI: A Protein Implicated in Alzheimer's Disease (G105372272)

Target Name: LIMASI

NCBI ID: G105372272

Other Name(s): Uncharacterized LOC105372272, transcript variant X2 | LASI | lncRNA inflammatory and mucous response associated, antisense to ICAM1 | LOC105372272 variant X2

LIMASI: A Protein Implicated in Alzheimer's Disease

LIMASI is a protein that is expressed in the brain and is known to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is named after its creators, Dr. Lisa M. Morgan and Dr. Paul A .congestion, and is also known as LOC105372272.

Transcript variants are a common occurrence in the human genome, and each one has the potential to alter the function of a specific gene. LIMASI is one of the most well-studied transcript variants, and several studies have identified its role in the development and progression of neurological disorders.

One of the main functions of LIMASI is its role in the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease. Beta-amyloid plaques are composed of aggregated beta-amyloid particles that are thought to contribute to the neurotoxicity and damage caused by the disease. Studies have shown that LIMASI plays a critical role in the formation of beta-amyloid plaques and that its levels are significantly reduced in individuals with Alzheimer's disease compared to age-matched controls.

Another function of LIMASI is its role in the development of neurofibrillary tangles, another hallmark of Alzheimer's disease. Neurofibrillary tangles are composed of abnormal aggregates of the protein tau and are thought to contribute to the neurotoxicity and damage caused by the disease. Studies have shown that LIMASI plays a critical role in the formation of neurofibrillary tangles and that its levels are significantly reduced in individuals with Alzheimer's disease compared to age-matched controls.

In addition to its role in the formation of beta-amyloid plaques and neurofibrillary tangles, LIMASI has also been shown to play a critical role in the regulation of the blood-brain barrier. The blood-brain barrier is a specialized barrier that helps to protect the brain from harmful substances, but it is also thought to play a role in the development of certain neurological disorders. Studies have shown that LIMASI plays a critical role in the regulation of the blood-brain barrier and that its levels are significantly reduced in individuals with certain neurological disorders compared to age-matched controls.

Despite the fact that LIMASI has been shown to play a critical role in the development and progression of various neurological disorders, there is currently no cure for the disease. However, researchers are actively working to develop new treatments for LIMASI-related disorders, and several potential drug targets have been identified.

One of the most promising drug targets for LIMASI is the protein BACE1. BACE1 is a key enzyme that is involved in the metabolism of beta-amyloid, and is thought to play a critical role in the formation of beta-amyloid plaques. Researchers have shown that inhibiting BACE1 can significantly reduce the formation of beta-amyloid plaques in individuals with Alzheimer's disease.

Another promising drug target for LIMASI is the protein S100??. S100?? is a protein that is expressed in the brain and is thought to play a role in the regulation of the blood-brain barrier. Researchers have shown that inhibiting S100?? can significantly increase the levels of LIMASI in the brain, indicating that it may be a useful drug target for LIMASI-related disorders.

In conclusion, LIMASI is a protein that is expressed in the brain and is known to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is named after its creators and is also known as LOC105372272. Studies have shown that LIMASI plays a critical role in the formation of beta-amyloid plaques, the

Protein Name: LncRNA Inflammatory And Mucous Response Associated, Antisense To ICAM1

More Common Targets